Presbia — Investor Presentation (May 2016)
31 slides from Presbia's investor presentation, May 18, 2016
Slide 1: May 2016 Investor Presentation
May 2016 Investor Presentation Exhibit 99.1
Slide 2: Disclosure
Disclosure To the extent statements contained in this presentation are not descriptions of historical facts regarding Presbia PLC and its subsidiaries (collectively “Presbia,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward
Slide 3: Business Highlights
Business Highlights Large, Underserved Presbyopia Opportunity Best-in-Class Near Vision Microlens Refractive corneal inlay restores reading vision, multiple lines of improvement Wide range of lens refractive powers to offer patients a customized therapy Compatible with other refractive surgical proc
Slide 4: Presbyopia Surgery is the Missing Piece in Refractive Surgery
Presbyopia Surgery is the Missing Piece in Refractive Surgery Hit hard by flat-to-declining LASIK procedure volumes, overcapacity, and LASIK procedure price erosion Highly receptive to new private pay presbyopia procedure requiring no capital outlay Refractive Surgery Centers No capital expenditure
Slide 5: A Loss of Near Vision Affecting the Majority of People over the Age of 40
A Loss of Near Vision Affecting the Majority of People over the Age of 40 Presbia and related research shows: The Inconvenience of Presbyopia “I can never find my glasses”* “Can’t read using my iPhone”* “The hassle of my glasses on and off all day”* Freedom and confidence Reading glasses are one of
Slide 6: Large, Underserved And Growing Market Opportunity
Large, Underserved And Growing Market Opportunity Demographic-Driven Market Growth 1.8 Billion Presbyopes (billions) Source: 2013 Market Scope. United States (113) Western Europe (128) Latin America (140) China (423) India (249) Rest of World (542) Other Wealthy Nations (53) Japan (58) (millions)
Slide 7: Safety Data (March 25, 2016)
Safety Data (March 25, 2016) 89 adverse events reported in operated eyes to date; majority easily treated No unanticipated adverse device effects reported to date Sept 2015: Completion of 2nd stage enrollment (a total of 346 subjects) Throughout 2016 into 2017: Focus is on compliance – constant subj
Slide 8: U.S. Pivotal Trial
U.S. Pivotal Trial Through March 31, 2016, 421 subjects have undergone insertion of the Company’s Microlens during the staged pivotal clinical trial to obtain pre-market approval from the FDA. Currently, the Company is 18 months into its 3-year pivotal study and anticipates submitting data to the FD
Slide 9: U.S. Pivotal Trial
U.S. Pivotal Trial Data made available to the Company indicates that: Subjects gained an average of 5 lines of uncorrected near visual acuity (the ability to see close objects without prescription enhancement) in treated eyes No change from results of 90% cohort reported Notwithstanding these result
Slide 10: In Summary (U.S. Pivotal Trial)
In Summary (U.S. Pivotal Trial) Can perform almost all near vision tasks without glasses An improvement from reading a subhead in the news paper (12pt font) to reading the content label (4pt font) on a bottle of eye drops
Slide 11: U.S. Pivotal Trial
U.S. Pivotal Trial There was little to no change in binocular uncorrected distance vision and no change from 90% cohort results reported Presbia Flexivue Microlens is designed to take advantage of binocular vision as most patients fuse both images in the brain. The brain filters bad images, thus, re
Slide 12: U.S. Pivotal Trial
U.S. Pivotal Trial Subjects gained an average of 5 lines of uncorrected near visual acuity (the ability to see close objects without enhancement) in treated eyes (Figure A). 82% of subjects achieved 20/40 or better uncorrected distance vision in treated eyes (Figure B). Figure B Figure A Notwithstan
Slide 13: U.S. Pivotal Trial
U.S. Pivotal Trial 98% of subjects achieved 20/40 or better best corrected distance vision in treated eyes (Figure C) and there was little to no change in binocular best corrected distance vision (Figure D). Figure C Figure D Notwithstanding these results, we cannot assure you when or whether the Co
Slide 14: Consistent with the recently reported data
Consistent with the recently report data Last month we reported on the data from 90% of the subjects who had passed through the 6-month post-operative visit. The results from the 100% of the subjects who have passed through the 6-month post operative visit show that we are consistently seeing subjec
Slide 15: Focused Commercialization Strategy
Focused Commercialization Strategy 2016 2017 2018 2019 South Korea Start to build clinical credibility in Germany Centers of Excellence: Ireland/UK, Netherlands, Australia/NZ, Canada Q4: North America* launch Asia: TBD: Japan, Malaysia, Singapore, Thailand Europe: TBD: Spain, Italy, Other Germany *
Slide 16: Two Pronged Approach in Country
Two Pronged Approach in Country * Contingent FDA approval Clinical Local data Local key opinion leader (KOL) Increase global data Local reference site (peer-to-peer education) PR driven by clinical data (positive clinical outcomes result in a believable and newsworthy campaign) Commercial Local expe
Slide 17: Focus Market South Korea – Key Activities Year To Date
Focus Market South Korea – Key Activities Year To Date Build acceptance through IRB/Clinical studies and surgical results High profile, respected clinical sites provide credibility with commercial surgeons and patients Short term clinical data (at months 3 and 6) Long-term studies (1 yr+) are used i
Slide 18: South Korea Targeted Marketing Program
South Korea Targeted Marketing Program (to be developed) Coordinated with key hospital Drive consumers to Presbia landing page and hospital call center
Slide 19: Korean Symposium – June
Korean Symposium – June Presentation of 1-year patient data from Korean surgeon Approximately 20 Korean surgeons participating Targeting those initial surgeons for commercial activity
Slide 20: The LASIK Perspective
The LASIK Perspective Country Population LASIK Cases (2013 Units) South Korea 49,000,000 139,000 Germany 81,000,000 135,000 The presbyopia market is approximately 1.6 times the size of the LASIK market. Source: 2012 Market Scope.
Slide 21: Clearly Differentiated Near Vision Solution
Clearly Differentiated Near Vision Solution
Slide 22: Procedure
Procedure Performed on one eye Utilizes proven laser technology to create a pocket in the cornea Customizable to specific patient vision needs 10-minute procedure in doctor’s office; topical anesthesia only Slit lamp image of Presbia Flexivue Microlens™ Presbia Flexivue Microlens™
Slide 23: Microlens Surgical Procedure
Microlens Surgical Procedure 10 Minute Procedure Utilizing Existing Femtosecond Laser Femtosecond Laser 1 Creates a pocket in patient’s cornea 3 2 Proprietary Inserters Surgeon uses inserter to implant lens in patient’s cornea Self-Sealing Pocket Pocket self-seals, holding lens in place at center of
Slide 24: Presbia Flexivue Microlens: Best In Class Solution
Intracorneal Refractive Lens implanted in a pocket in cornea of non-dominant eye Hydrophilic Acrylic Material similar to that used in IOLs for > 20 years A True “Microlens” with 3.2 mm diameter and edge thickness of 0.015 mm Offered In A Wide Range Of Powers ranging from +1.5 diopter to +3.5 diopter
Slide 25: Not All Inlays are the Same
Not All Inlays are the Same Intracorneal Refractive Lens; Implanted in a Pocket Creates a Pinhole Effect; Implanted in a Pocket AcuFocus KAMRA Adds Bulk to Cornea; Implanted under a LASIK-like Flap ReVision Optics Raindrop Wide Range of Refractive Powers ü X X Aesthetically Appealing ü X ü Designed
Slide 26: Intellectual Property
Intellectual Property Five patents issued: Lens Holder Apparatus and System Method (US 8,869,975 B2) Lens Inserter Apparatus and Method (US 9,017,401 B2) Lens Injector Apparatus and Method (US 8,454,687 B2) Lens Injector Apparatus System and Method (US 9,010,817 B2) Method for Laser Cutting a Cornea
Slide 27: Manufacturing
Manufacturing 4,000 square-foot, two-part (wet/dry) manufacturing facility Approved to manufacture devices for U.S. IDE by State of California FDA in 2013 Sufficient capacity to handle projected Presbia Flexivue Microlens™ volume through U.S. launch Approved to manufacture devices for OUS sale by In
Slide 28: Experienced Leadership Team & Board
Experienced Leadership Team & Board Vanessa Tasso Vice President of Clinical Affairs John Strobel Vice President of Sales Vlad Feingold Chief Technology Officer & Director Todd Cooper President, Chief Executive Officer & Director Randy Thurman Executive Chairman Richard Ressler Director Bob Cresci D
Slide 29: Business Highlights
Business Highlights Large, Underserved Presbyopia Opportunity Best-in-Class Near Vision Microlens Refractive corneal inlay restores reading vision, multiple lines of improvement Wide range of lens refractive powers to offer patients a customized therapy Compatible with other refractive surgical proc
Slide 30: Words From Our Surgeons
Words From Our Surgeons "Thank you for enabling us to implant an invisible product into a transparent organ, with dogma defying outcomes and joyous recipients. It is these inspiring experiences that make medicine fun". Kerry Assil, MD (USA) “It (Presbia Microlens) marks a new era in the treatment of
Slide 31: Presbia PLC Headquarters and Offices
Presbia PLC (Headquarters) 120-121 Lower Baggot St. Dublin 2, Ireland tel: +353-1-659-9446 Presbia Coöperatief U.A. Pieter Pauwstraat 2A – I · 1017 ZJ Amsterdam, Netherlands tel: +31-20-7084-556 · fax: +31-20-7084-556 PresbiBio LLC 8845 Irvine Center Dr., Suite 100 · Irvine, CA 92618 tel: +1-949‐502